先聲藥業(02096.HK)腫瘤創新藥科賽拉獲准常規上市

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

先聲藥業(02096.HK)腫瘤創新藥科賽拉獲准常規上市

阿思達克 10-31 01:59

先聲藥業(02096.HK)公布，集團腫瘤領域創新藥科賽拉(注射用鹽酸曲拉西利)已達成補充申請條件，獲國家藥品監督管理局批准由附條件上市轉為常規上市，適應症為適用於既往未接受過系統性化療的廣泛期小細胞肺癌患者在接受含鉑類藥物聯合依托泊甘方案治療前給藥，以降低化療引起的骨髓抑制發生率。

先聲藥業(02096.HK)

Relevant Stocks

先聲藥業(02096.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

先聲藥業(02096.HK)腫瘤創新藥科賽拉獲准常規上市

Services

About Us

Agreement Statement